12(top 5%)
papers
425(top 2%)
citations
6(top 5%)
h-index
10(top 5%)
g-index
12
all documents
466
doc citations
210
citing journals

Top Articles

#TitleJournalYearCitations
1S100-Beta, Melanoma-Inhibiting Activity, and Lactate Dehydrogenase Discriminate Progressive From Nonprogressive American Joint Committee on Cancer Stage IV MelanomaJournal of Clinical Oncology1999240
2Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Journal of Clinical Oncology202359
3Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis202146
4Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 TrialJournal of Clinical Oncology202335
5Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysatesCancer Immunology, Immunotherapy200425
6Combined treatment with pegylated interferon–α‐2a and dacarbazine in patients with advanced metastatic melanomaCancer200822
7Effect of a Face-Aging Mobile App–Based Intervention on Skin Cancer Protection Behavior in Secondary Schools in BrazilJAMA Dermatology202021
8Pitfalls in the clinical application of monoclonal antibodies in malignant melanoma: modulation by and impaired accessibility of antigens to monoclonal antibodiesCancer Treatment Reviews19906
9Imatinib in locally advanced dermatofibrosarcoma protuberans (DFSP): A phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)Journal of Clinical Oncology20066
10Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?Cancer Immunology, Immunotherapy20045
11Positron Emission Tomography (PET)Melanoma Research19931
12Enabling successful T-cell therapy of solid tumors with oncolytic adenoviruses armed with TNF&agr; and IL-2Annals of Oncology20160